
Opinion|Videos|January 22, 2025
CLEAR-Outcomes Data: Primary Prevention With Bempedoic Acid
Key Takeaways
- Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
- Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Panelists discuss how the CLEAR-outcomes trial demonstrated bempedoic acid’s efficacy in primary prevention of cardiovascular events, informing its clinical implementation for patients with statin intolerance or inadequate LDL-C control.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- The primary prevention data with bempedoic acid from CLEAR-outcomes are exciting. Could you review the data and how you use BA in your practice?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
2
Prevalence and Recognition of Hypercortisolism
3
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
4
Diagnosing the Hallmark Signs and Symptoms of CSU
5

























































































